Trial reportThe Journal of clinical endocrinology and metabolism2012
Impact of mifepristone, a glucocorticoid/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function.
Trial report in The Journal of clinical endocrinology and metabolism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- The effect of hypercortisolism treatment on dyslipidemia in Cushing syndrome: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Long-term green-Mediterranean diet may favor fasting morning cortisol stress hormone; the DIRECT-PLUS clinical trial.Frontiers in endocrinology · 2023Trial
- Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Mifepristone Improves Adipose Tissue Insulin Sensitivity in Insulin Resistant Individuals.The Journal of clinical endocrinology and metabolism · 2021Trial
- Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study.Frontiers in endocrinology · 2021Trial
- Trial
- Nomogram for predicting cardiovascular disease mortality in patients with meningioma: a competing risk analysis.Neurosurgical review · 2023Article
- Exploring the role of uterine fibroids in promotion of cardiovascular diseases by diabetes exposure: Findings from national health and nutrition examination survey 1999-2006.Frontiers in cardiovascular medicine · 2022Article
- Glucocorticoid Receptor Antagonism as a New "Remedy" for Insulin Resistance-Not There Yet!The Journal of clinical endocrinology and metabolism · 2021Article
- Gender-Specific Independent and Combined Effects of the Progesterone and 17-Hydroxyprogesterone on Metabolic Syndrome: From the Henan Rural Cohort Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations.Clinical diabetes and endocrinology · 2020Review
- Evaluation of Evidence of Adrenal Insufficiency in Trials of Normocortisolemic Patients Treated With Mifepristone.Journal of the Endocrine Society · 2017Article
- Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.British journal of pharmacology · 2012Review
- Biochemical and Radiological Changes in Liver Steatosis Following Mifepristone Treatment in Patients With Hypercortisolism.AACE clinical case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
Abstract
contextMifepristone is a glucocorticoid and progestin antagonist under investigation for the treatment of Cushing's syndrome. Mifepristone decreases high-density lipoprotein (HDL) cholesterol (HDL-C) levels in treated patients, but the clinical significance of this is unclear because recent studies suggest that functional properties of HDL predict cardiovascular disease status better than does HDL-C concentration.
objectiveThe aim of the study was to characterize the impact of mifepristone administration on HDL particle concentration and function. DESIGN AND
settingWe conducted a double-blind, randomized, placebo-controlled trial at a single-site, clinical research center.
participantsThirty healthy postmenopausal female volunteers participated in the study.
interventionIndividuals were randomized to receive daily oral mifepristone (600 mg) or placebo for 6 wk.
main outcome measuresWe measured HDL-C, serum HDL particle concentration, and HDL-mediated cholesterol efflux by treatment group.
resultsAs expected, ACTH, cortisol, estradiol, and testosterone levels increased in the mifepristone group. Mifepristone treatment decreased HDL-C and HDL particle concentration by 26 and 25%, respectively, but did not alter pre-β HDL concentration. In contrast, the serum HDL-mediated cholesterol efflux decreased with mifepristone treatment by only 12%, resulting in an effective increase of the efflux capacity per HDL particle. No changes were observed in cholesterol ester transfer protein or lecithin:cholesterol acyltransferase activity.
conclusionsTreatment with mifepristone reduced HDL-C, HDL particle concentration, and serum HDL cholesterol efflux in postmenopausal women. However, on a per particle basis, the efflux capacity of serum HDL increased. These observations support the concept that a decrease in HDL-C may not represent proportional impairment of HDL function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.